Cargando…
Adenylosuccinic Acid: An Orphan Drug with Untapped Potential
Adenylosuccinic acid (ASA) is an orphan drug that was once investigated for clinical application in Duchenne muscular dystrophy (DMD). Endogenous ASA participates in purine recycling and energy homeostasis but might also be crucial for averting inflammation and other forms of cellular stress during...
Autores principales: | Rybalka, Emma, Kourakis, Stephanie, Bonsett, Charles A., Moghadaszadeh, Behzad, Beggs, Alan H., Timpani, Cara A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304260/ https://www.ncbi.nlm.nih.gov/pubmed/37375769 http://dx.doi.org/10.3390/ph16060822 |
Ejemplares similares
-
Adenylosuccinic Acid Is a Non-Toxic Small Molecule In Vitro and In Vivo
por: Timpani, Cara A., et al.
Publicado: (2023) -
Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophy
por: Timpani, Cara A., et al.
Publicado: (2020) -
Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19
por: Timpani, Cara A., et al.
Publicado: (2020) -
Micro (mRNA) molecules could pack a big punch in the fight against neuromuscular disease
por: Rybalka, Emma, et al.
Publicado: (2020) -
Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?
por: Kourakis, Stephanie, et al.
Publicado: (2020)